Skip to main content

CND’s Synuclein-One Study Results Published in the Journal of American Medical Association. See the release

Senior woman header
Senior woman header
Photo header of senior man
Photo header of senior man

DIAGNOSTIC INSIGHTS FOR LIFE

CND’s Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.

Learn More
Senior woman header
Senior woman header
Senior man header
Photo header of senior man

DIAGNOSTIC INSIGHTS FOR LIFE

CND’s Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.

Learn More

Introducing the Syn-One Test® from CND Life Sciences

The first commercially available skin-based test to help clinicians diagnose Parkinson’s disease and related disorders.

seal icon

CLIA-Certified and CAP-Accredited Pathology Lab

test tube icon

Dedication to Science, Research, Quality, and Reliability

DNA icon

Patient-Focused Mission

microscope icon

High Accuracy: >95% Sensitivity and Specificity

Clarity and Confidence of Syn-One

Having objective, visual proof of a disease process can be invaluable for physicians and patients. That’s why CND Life Sciences developed the Syn-One Test as a way to actually see the presence of abnormal alpha-synuclein in the skin–an important marker for Parkinson’s disease and other disorders known as synucleinopathies.  

Learn More

Our Commitment to Patients

We did not invent the saying “knowledge is power,” but we subscribe to this philosophy as part of our mission. Patients and caregivers rely on physicians to make vital clinical judgments every day, and we are committed to providing reliable diagnostic technologies and useful insights that help optimize care.

Learn more about what drives us.

Learn More

CND Insights

Read our perspectives on the industry, the field of neurodiagnostics, patient care, and other topics.

Insights
March 13, 2024

Understanding Genetics and Inflammation in Parkinson’s Disease: More Ammunition in the Battle Against Parkinson’s

“Genetics loads the gun and environment pulls the trigger” is often invoked when discussing the…
Insights
February 13, 2024

Syn-One Test® Features Prominently in NeurologyLive MEDcast Episode

NeurologyLive’s MEDcast recently released an episode titled “Paradigm Shift in Parkinson’s Disease Diagnosis” that included…
Insights
February 7, 2024

The Role of Environmental Toxins in Parkinson’s Disease Risk

As 2023 drew to a close, the Parkinson’s community worked together to bring important legislation…
VIEW ALL INSIGHTS

News

Check out press releases, news alerts and coverage of CND happenings.

News Release
March 20, 2024

Breakthrough Results of NIH-Sponsored Study of Syn-One Test® as a Skin-Based Diagnostic Tool for Parkinson’s Disease and Related Disorders Published in the Journal of the American Medical Association

CND Life Sciences (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests…
News Release
March 5, 2024

CND Life Sciences Partners with Visiopharm on Novel AI-Tool to Detect and Quantify Pathological Alpha-Synuclein in Cutaneous Nerves

March 5, 2024 – Scottsdale, Ariz – CND Life Sciences (CND), a medical technology company…
On Our Radar
February 29, 2024

Seven Molecules Identified as Potential Treatments for Familial Parkinson’s

Conscience, a Canadian nonprofit biotech company, announced last month that seven molecules had been identified…
VIEW ALL NEWS
CND CASE STUDIES

For Clinicians: Request a Skin Biopsy Test Kit

Our suite of neurodiagnostic tests provides clinicians with objective pathological insights on diseases that are often difficult to diagnose. Using our free Skin Biopsy Test Kit, simply collect three small skin biopsies from your patient, send them to our CLIA-certified and CAP-accredited lab, and CND will provide important pathological insights to support a diagnosis.

Order a Kit